The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
At least when we look at the receptor we found for leucine, and then we look at the concentrations at which it might bind the other branched -chain amino acids, we don't think those affinities are relevant. Particularly valine is way too low. Isoleucine maybe in some situations could act through the receptor, but unlikely.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.